Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention At IAS 2021

07/20/2021 | 06:00am EDT

Merck announced results from a Phase 2a clinical trial evaluating the safety, tolerability and pharmacokinetics (PK) of six monthly oral doses, over 24 weeks, of islatravir, the company’s investigational nucleoside reverse transcriptase translocation inhibitor, versus placebo for pre-exposure prophylaxis (PrEP) of HIV-1 infection in adults at low-risk of contracting HIV-1. After 24 weeks, once-monthly oral islatravir was generally well tolerated versus placebo. Most adverse events (AEs) were mild and there were no serious drug-related AEs in people who received islatravir. The levels of islatravir in peripheral blood mononuclear cells also remained above the pre-specified efficacy PK threshold for PrEP at both doses studied (60 mg and 120 mg) eight weeks after the last study dose. These data were shared as a late-breaking oral presentation during the virtual 11thInternational AIDS Society Conference on HIV Science (IAS 2021) and are a follow-up to the interim analysis that was presented earlier in 2021 at the virtual 2021 HIV Research for Prevention Conference.


© S&P Capital IQ 2021
All news about MERCK & CO., INC.
10:51aMERCK : Thinking about trading options or stock in Draftkings, Merck, ConocoPhillips, Walg..
PR
07:02aMERCK : Building Sustainable Value for our Business and Society
PU
09/20MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Ris..
AQ
09/20MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Che..
AQ
09/20MERCK : Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination With..
AQ
09/20MERCK : KEYTRUDA (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in P..
AQ
09/19MERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Ch..
BU
09/18MERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Ri..
BU
09/18MERCK : KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in ..
BU
09/18Merck Announces the First Results from the Phase 3 Keynote-716 Trial
CI
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 15,7x
Yield 2021 3,60%
Capitalization 182 B 182 B -
EV / Sales 2021 4,21x
EV / Sales 2022 3,81x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 71,93 $
Average target price 93,42 $
Spread / Average Target 29,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-12.07%182 082
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000